Targeting Cancer Hallmarks Using Selected Food Bioactive Compounds: Potentials for Preventive and Therapeutic Strategies
Abstract
:1. Introduction
2. Methodology
3. The Hallmarks of Cancer
3.1. Sustaining Proliferative Signaling
3.1.1. Alteration of Extracellular Growth Signals
3.1.2. Alterations in Transcellular Transducers Responsible for Growth Signals
3.1.3. Alteration of Intracellular Circuits and Cytosolic Signaling Molecules
3.2. Evading Growth Suppressors
3.3. Resisting Cell Death
3.3.1. Apoptosis
3.3.2. Autophagy
3.3.3. Necrosis
3.4. Enabling Replicative Immortality
3.5. Inducing or Accessing Vasculature
3.6. Activating Invasion and Metastasis
3.7. Reprogramming Cellular Metabolism
3.8. Avoiding Immune Destruction
3.9. Phenotypic Plasticity and Disrupted Differentiation
4. Bioactive Compounds in Food with Anticancer Activity
4.1. Thymoquinone
4.2. Resveratrol
4.3. Piperine
4.4. Genistein
4.5. Allicin
4.6. Epigallocatechin Gallate
4.7. Curcumin
4.8. Emodin
4.9. Parthenolide
4.10. Luteolin
4.11. Quercetin
4.12. Anthocyanins
5. Dietary Management with Cancer Prevention Potential
5.1. Inflammation-Reducing Diet
5.2. Alkaline Diet
5.3. Ketogenic Diet
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO EML Cancer Medicines Working Group (CMWG): Report of the Meeting 22–23 March 2018, Geneva, Switzerland. Available online: https://iris.who.int/handle/10665/272962 (accessed on 21 August 2024).
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Abbafati, C.; Abbas, K.M.; Abbasi, M.; Abbasifard, M.; Abbasi-Kangevari, M.; Abbastabar, H.; Abd-Allah, F.; Abdelalim, A.; Abdollahi, M.; Abdollahpour, I.; et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–1222. [Google Scholar]
- Naghavi, M.; Abajobir, A.A.; Abbafati, C.; Abbas, K.; Abd-Allah, F.; Abera, S.; Aboyans, V.; Adetokunboh, O.; Ärnlöv, J.; Afshin, A.; et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1151–1210. [Google Scholar] [CrossRef]
- Shurrab, S.A.; Al-Badarneh, A.F.; Nassar, H.I.; Almshnanah, A.H. Cancer in Five Countries of the Eastern Mediterranean Region: Epidemiological Trends and Risk Implications. Niger. J. Clin. Pract. 2022, 25, 78–84. [Google Scholar]
- Ding, D.; Lawson, K.D.; Kolbe-Alexander, T.L.; Finkelstein, E.; Katzmarzyk, P.; van Mechelen, W.; Pratt, M. The economic burden of physical inactivity: A global analysis of major non-communicable diseases. Lancet 2016, 388, 1311–1324. [Google Scholar] [CrossRef] [PubMed]
- Colditz, G.A.; Wolin, K.Y.; Gehlert, S. Applying What We Know to Accelerate Cancer Prevention. Sci. Transl. Med. 2012, 4, 127rv4. [Google Scholar] [CrossRef] [PubMed]
- World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: A Global Perspective A summary of the Third Expert Report 2018. Available online: https://www.wcrf.org/wp-content/uploads/2021/02/Summary-of-Third-Expert-Report-2018.pdf (accessed on 21 August 2024).
- Brennan, P.; Davey-Smith, G. Identifying Novel Causes of Cancers to Enhance Cancer Prevention: New Strategies Are Needed. J. Natl. Cancer Inst. 2022, 114, 353–360. [Google Scholar] [CrossRef]
- Colditz, G.A.; Wei, E.K. Preventability of cancer: The relative contributions of biologic and social and physical environmental determinants of cancer mortality. Annu. Rev. Public Health 2012, 33, 137–156. [Google Scholar] [CrossRef]
- Du, H.; Li, L.; Bennett, D.; Yang, L.; Guo, Y.; Key, T.; Bian, Z.; Chen, Y.; Walters, R.; Millwood, I.; et al. Fresh fruit consumption and all-cause and cause-specific mortality: Findings from the China Kadoorie Biobank. Int. J. Epidemiol. 2017, 46, 1444–1455. [Google Scholar] [CrossRef]
- Cirmi, S.; Navarra, M.; Woodside, J.V.; Cantwell, M.M. Citrus fruits intake and oral cancer risk: A systematic review and meta-analysis. Pharmacol. Res. 2018, 133, 187–194. [Google Scholar] [CrossRef]
- Barreca, D.; Gattuso, G.; Bellocco, E.; Calderaro, A.; Trombetta, D.; Smeriglio, A.; Laganà, G.; Daglia, M.; Meneghini, S.; Nabavi, S. Flavanones: Citrus phytochemical with health-promoting properties. Biofactors 2017, 43, 495–506. [Google Scholar] [CrossRef] [PubMed]
- Bae, J.M.; Kim, E.H. Dietary intakes of citrus fruit and risk of gastric cancer incidence: An adaptive meta-analysis of cohort studies. Epidemiol. Health 2016, 38, e2016034. [Google Scholar] [CrossRef] [PubMed]
- Schwedhelm, C.; Boeing, H.; Hoffmann, G.; Aleksandrova, K.; Schwingshackl, L. Effect of diet on mortality and cancer recurrence among cancer survivors: A systematic review and meta-analysis of cohort studies. Nutr. Rev. 2016, 74, 737–748. [Google Scholar] [CrossRef] [PubMed]
- Amiot-Carlin, M.J. Fruit and vegetable consumption: What benefits, what risks? Rev. Prat. 2019, 69, 139–142. [Google Scholar] [PubMed]
- Baena Ruiz, R.; Salinas Hernández, P. Cancer chemoprevention by dietary phytochemicals: Epidemiological evidence. Maturitas 2016, 94, 13–19. [Google Scholar] [CrossRef]
- Bolhassani, A.; Khavari, A.; Bathaie, S.Z. Saffron and natural carotenoids: Biochemical activities and anti-tumor effects. Biochim. Biophys. Acta 2014, 1845, 20–30. [Google Scholar] [CrossRef]
- Vemuri, S.K.; Banala, R.R.; Subbaiah, G.P.V.; Srivastava, S.K.; Reddy, A.V.G.; Malarvili, T. Anti-cancer potential of a mix of natural extracts of turmeric, ginger and garlic: A cell-based study. Egypt. J. Basic. Appl. Sci. 2017, 4, 332–344. [Google Scholar] [CrossRef]
- Wu, S.; Zhu, W.; Thompson, P.; Hannun, Y.A. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat. Commun. 2018, 9, 3490. [Google Scholar] [CrossRef]
- Niemans, R.S.T. Exploiting Tumor Hypoxia for Cancer Treatment. Doctoral Thesis, Maastricht University, Maastricht, The Netherlands, 2018. [Google Scholar] [CrossRef]
- Alcolea, M.P.; Alonso-Curbelo, D.; Ambrogio, C.; Bullman, S.; Correia, A.; Ernst, A.; Halbrook, C.; Kelly, G.; Lund, A.; Quail, D.; et al. Cancer Hallmarks: Piecing the Puzzle Together. Cancer Discov. 2024, 14, 674–682. [Google Scholar] [CrossRef]
- Mokhtari, R.B.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating cancer. Oncotarget 2017, 8, 38022–38043. [Google Scholar] [CrossRef]
- Ravi, S.; Alencar, A.M., Jr.; Arakelyan, J.; Xu, W.; Stauber, R.; Wang, C.; Papyan, R.; Ghazaryan, N.; Pereira, R. An Update to Hallmarks of Cancer. Cureus 2022, 14, e24803. [Google Scholar] [CrossRef]
- Neophytou, C.M.; Panagi, M.; Stylianopoulos, T.; Papageorgis, P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers 2021, 13, 2053. [Google Scholar] [CrossRef] [PubMed]
- Arneth, B. Tumor Microenvironment. Medicina 2019, 56, 15. [Google Scholar] [CrossRef] [PubMed]
- Mierke, C.T. Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells. Cells 2024, 13, 96. [Google Scholar] [CrossRef] [PubMed]
- Winkler, J.; Abisoye-Ogunniyan, A.; Metcalf, K.J.; Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 2020, 11, 5120. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. Biological Hallmarks of Cancer. Holl.-Frei Cancer Med. 2017, 1, 1–10. [Google Scholar]
- Martin-Fernandez, M.L.; Clarke, D.T.; Roberts, S.K.; Zanetti-Domingues, L.C.; Gervasio, F.L. Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. Cells 2019, 8, 316. [Google Scholar] [CrossRef] [PubMed]
- Witsch, E.; Sela, M.; Yarden, Y. Roles for Growth Factors in Cancer Progression. Physiology 2010, 25, 85–101. [Google Scholar] [CrossRef]
- Baghban, R.; Roshangar, L.; Jahanban-Esfahlan, R.; Seidi, K.; Ebrahimi-Kalan, A.; Jaymand, M.; Kolahian, S.; Javaheri, T.; Zare, P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020, 18, 59. [Google Scholar] [CrossRef]
- Yarden, Y.; Ullrich, A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 1988, 57, 443–478. [Google Scholar] [CrossRef] [PubMed]
- Kajanne, R. Activator Protein-1 and Epidermal Growth Factor Receptor Interplay: In Vivo & In Vitro Studies; Helsinki University Biomedical Dissertations; nro. 125; Helsingin yliopisto: Helsinki, Finland, 2009; 81p, Available online: http://urn.fi/URN:ISBN:978-952-10-5694-9 (accessed on 21 August 2024).
- Ferguson, K.M. Structure-based view of epidermal growth factor receptor regulation. Annu. Rev. Biophys. 2008, 37, 353–373. [Google Scholar] [CrossRef] [PubMed]
- Wee, P.; Wang, Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 2017, 9, 52. [Google Scholar] [CrossRef] [PubMed]
- Davies, M.A.; Samuels, Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010, 29, 5545–5555. [Google Scholar] [CrossRef]
- Yuan, T.L.; Cantley, L.C. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 2008, 27, 5497–5510. [Google Scholar] [CrossRef]
- Chalak, M.; Hesaraki, M.; Mirbahari, S.N.; Yeganeh, M.; Abdi, S.; Rajabi, S.; Hemmatzadeh, F. Cell Immortality: In Vitro Effective Techniques to Achieve and Investigate Its Applications and Challenges. Life 2024, 14, 417. [Google Scholar] [CrossRef]
- Thakur, A.; Faujdar, C.; Sharma, R.; Sharma, S.; Malik, B.; Nepali, K.; Liou, J. Glioblastoma: Current Status, Emerging Targets, and Recent Advances. J. Med. Chem. 2022, 65, 8596–8685. [Google Scholar] [CrossRef]
- Greten, F.R.; Grivennikov, S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 2019, 51, 27–41. [Google Scholar] [CrossRef] [PubMed]
- Seoane, J.; Gomis, R.R. TGF-β Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harb. Perspect. Biol. 2017, 9, 22277–22278. [Google Scholar] [CrossRef]
- Morana, O.; Wood, W.; Gregory, C.D. The Apoptosis Paradox in Cancer. Int. J. Mol. Sci. 2022, 23, 1328. [Google Scholar] [CrossRef]
- Fouad, Y.A.; Aanei, C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 2017, 7, 1016. [Google Scholar] [PubMed]
- Xu, X.; Lai, Y.; Hua, Z.C. Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Biosci. Rep. 2019, 39, BSR20180992. [Google Scholar] [CrossRef] [PubMed]
- Singh, R.; Letai, A.; Sarosiek, K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 2019, 20, 175. [Google Scholar] [CrossRef]
- Algar, W.R.; Jeen, T.; Massey, M.; Peveler, W.J.; Asselin, J. Small Surface, Big Effects, and Big Challenges: Toward Understanding Enzymatic Activity at the Inorganic Nanoparticle-Substrate Interface. Langmuir 2019, 35, 7067–7091. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef]
- White, E.; DiPaola, R.S. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 2009, 15, 5308–5316. [Google Scholar] [CrossRef]
- Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, Inflammation, and Cancer. Cell 2010, 140, 883. [Google Scholar] [CrossRef] [PubMed]
- Muraki, K.; Nyhan, K.; Han, L.; Murnane, J.P. Mechanisms of telomere loss and their consequences for chromosome instability. Front. Oncol. 2012, 2, 135. [Google Scholar] [CrossRef]
- Faubert, B.; Solmonson, A.; DeBerardinis, R.J. Metabolic reprogramming and cancer progression. Science 2020, 368, eaaw5473. [Google Scholar] [CrossRef]
- Lugano, R.; Ramachandran, M.; Dimberg, A. Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 2020, 77, 1745–1770. [Google Scholar] [CrossRef]
- Liao, C.; Liu, X.; Zhang, C.; Zhang, Q. Tumor hypoxia: From basic knowledge to therapeutic implications. Semin. Cancer Biol. 2023, 88, 172–186. [Google Scholar] [CrossRef] [PubMed]
- Jiang, W.G.; Sanders, A.J.; Katoh, M.; Ungefroren, H.; Gieseler, F.; Prince, M.; Thompson, S.K.; Zollo, M.; Spano, D.; Dhawan, P.; et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin. Cancer Biol. 2015, 35, S244–S275. [Google Scholar] [CrossRef]
- Ganapathy-Kanniappan, S.; Geschwind, J.F.H. Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol. Cancer 2013, 12, 152. [Google Scholar] [CrossRef] [PubMed]
- de la Cruz-López, K.G.; Castro-Muñoz, L.J.; Reyes-Hernández, D.O.; García-Carrancá, A.; Manzo-Merino, J. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front. Oncol. 2019, 9, 1143. [Google Scholar] [CrossRef]
- Finn, O.J. Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 2012, 23, viii6–viii9. [Google Scholar] [CrossRef]
- -López, R.; Kandeel, M. Oncogenic Viruses-Encoded microRNAs and Their Role in the Progression of Cancer: Emerging Targets for Antiviral and Anticancer Therapies. Pharmaceuticals 2023, 16, 485. [Google Scholar] [CrossRef] [PubMed]
- Yuan, S.; Norgard, R.J.; Stanger, B.Z. Cellular Plasticity in Cancer. Cancer Discov. 2019, 9, 837–851. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022, 12, 31–46. [Google Scholar] [CrossRef]
- Castro-Pérez, E.; Singh, M.; Sadangi, S.; Mela-Sánchez, C.; Setaluri, V. Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance. Pigment. Cell Melanoma Res. 2023, 36, 330–347. [Google Scholar] [CrossRef]
- Ahmad, A.; Mishra, R.K.; Vyawahare, A.; Kumar, A.; Rehman, M.U.; Qamar, W.; Khan, A.Q.; Khan, R. Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects. Saudi Pharm. J. 2019, 27, 1113–1126. [Google Scholar] [CrossRef]
- Dajani Esam, Z.; Shahwan, T.G.; Dajani, N.E. Overview of the preclinical pharmacological properties of Nigella sativa (black seeds): A complementary drug with historical and clinical significance. J. Physiol. Pharmacol. 2016, 67, 801–817. [Google Scholar]
- Younus, H. Molecular and Therapeutic actions of Thymoquinone: Actions of Thymoquinone. In Molecular and Therapeutic Actions of Thymoquinone: Actions of Thymoquinone; Springer Nature: Singapore, 2018; ISBN 978-981-10-8800-1. [Google Scholar]
- Darakhshan, S.; Bidmeshki Pour, A.; Hosseinzadeh Colagar, A.; Sisakhtnezhad, S. Thymoquinone and its therapeutic potentials. Pharmacol. Res. 2015, 95–96, 138–158. [Google Scholar] [CrossRef]
- Alobaedi, O.H.; Talib, W.H.; Basheti, I.A. Antitumor effect of thymoquinone combined with resveratrol on mice transplanted with breast cancer. Asian Pac. J. Trop. Med. 2017, 10, 400–408. [Google Scholar] [CrossRef] [PubMed]
- Kou, B.; Liu, W.; Zhao, W.; Duan, P.; Yang, Y.; Yi, Q.; Guo, F.; Li, J.; Zhou, J.; Kou, Q. Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway. Oncol. Rep. 2017, 38, 3592–3598. [Google Scholar] [CrossRef]
- Feng, L.M.; Wang, X.F.; Huang, Q.X. Thymoquinone induces cytotoxicity and reprogramming of EMT in gastric cancer cells by targeting PI3K/Akt/mTOR pathway. J. Biosci. 2017, 42, 547–554. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Du, H.; Huang, Z.; Zhang, P.; Yue, Y.; Wang, W.; Liu, W.; Zeng, J.; Ma, J.; Chen, G.; et al. Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway. Chem. Biol. Interact. 2018, 292, 65–75. [Google Scholar] [CrossRef]
- Khan, M.A.; Tania, M.; Fu, J. Epigenetic role of thymoquinone: Impact on cellular mechanism and cancer therapeutics. Drug Discov. Today 2019, 24, 2315–2322. [Google Scholar] [CrossRef] [PubMed]
- Mahmoud, Y.K.; Abdelrazek, H.M.A. Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy. Biomed. Pharmacother. 2019, 115, 108783. [Google Scholar] [CrossRef]
- Phua, C.Y.H.; Teoh, Z.L.; Goh, B.H.; Yap, W.H.; Tang, Y.Q. Triangulating the pharmacological properties of thymoquinone in regulating reactive oxygen species, inflammation, and cancer: Therapeutic applications and mechanistic pathways. Life Sci. 2021, 287, 120120. [Google Scholar] [CrossRef]
- Homayoonfal, M.; Asemi, Z.; Yousefi, B. Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis. Cell. Mol. Biol. Lett. 2022, 27, 21. [Google Scholar] [CrossRef]
- Farghaly, M.E.; Khowailed, A.A.; Aboulhoda, B.E.; Rashed, L.A.; Gaber, S.S.; Ashour, H. Thymoquinone Potentiated the Anticancer Effect of Cisplatin on Hepatic Tumorigenesis by Modulating Tissue Oxidative Stress and Endoplasmic GRP78/CHOP Signaling. Nutr. Cancer 2022, 74, 278–287. [Google Scholar] [CrossRef] [PubMed]
- Bashmail, H.A.; Alamoudi, A.A.; Noorwali, A.; Hegazy, G.A.; Ajabnoor, G.M.; Al-Abd, A.M. Thymoquinone Enhances Paclitaxel Anti-Breast Cancer Activity via Inhibiting Tumor-Associated Stem Cells Despite Apparent Mathematical Antagonism. Molecules 2020, 25, 426. [Google Scholar] [CrossRef]
- Gali-Muhtasib, H.U.; Abou Kheir, W.G.; Kheir, L.A.; Darwiche, N.; Crooks, P.A. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs 2004, 15, 389–399. [Google Scholar] [CrossRef]
- Alhmied, F.; Alammar, A.; Alsultan, B.; Alshehri, M.; Pottoo, F.H. Molecular Mechanisms of Thymoquinone as Anticancer Agent. Comb. Chem. High. Throughput Screen. 2021, 24, 1644–1653. [Google Scholar] [CrossRef]
- Ma, J.; Zhang, Y.; Deng, H.; Liu, Y.; Lei, X.; He, P.; Dong, W. Thymoquinone inhibits the proliferation and invasion of esophageal cancer cells by disrupting the AKT/GSK-3β/Wnt signaling pathway via PTEN upregulation. Phytother. Res. 2020, 34, 3388–3399. [Google Scholar] [CrossRef]
- Shrikanta, A.; Kumar, A.; Govindaswamy, V. Resveratrol content and antioxidant properties of underutilized fruits. J. Food Sci. Technol. 2015, 52, 383. [Google Scholar] [CrossRef]
- Hasan, M.M.; Bae, H. An Overview of Stress-Induced Resveratrol Synthesis in Grapes: Perspectives for Resveratrol-Enriched Grape Products. Molecules 2017, 22, 294. [Google Scholar] [CrossRef]
- Kapetanovic, I.M.; Muzzio, M.; Huang, Z.; Thompson, T.N.; McCormick, D.L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2011, 68, 593–601. [Google Scholar] [CrossRef] [PubMed]
- Gambini, J.; Inglés, M.; Olaso, G.; Lopez-Grueso, R.; Bonet-Costa, V.; Gimeno-Mallench, L.; Mas-Bargues, C.; Abdelaziz, K.M.; Gomez-Cabrera, M.C.; Vina, J.; et al. Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxid. Med. Cell. Longev. 2015, 2015, 837042. [Google Scholar] [CrossRef]
- Caruso, F.; Tanski, J.; Villegas-Estrada, A.; Rossi, M. Structural basis for antioxidant activity of trans-resveratrol: Ab initio calculations and crystal and molecular structure. J. Agric. Food Chem. 2004, 52, 7279–7285. [Google Scholar] [CrossRef]
- Tian, B.; Liu, J. Resveratrol: A review of plant sources, synthesis, stability, modification and food application. J. Sci. Food Agric. 2020, 100, 1392–1404. [Google Scholar] [CrossRef]
- Galiniak, S.; Aebisher, D.; Bartusik-Aebisher, D. Health benefits of resveratrol administration. Acta Biochim. Pol. 2019, 66, 13–21. [Google Scholar] [CrossRef]
- Meng, X.; Zhou, J.; Zhao, C.N.; Gan, R.Y.; Li, H.B. Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review. Foods 2020, 9, 340. [Google Scholar] [CrossRef]
- Tresserra-Rimbau, A.; Rimm, E.B.; Medina-Remón, A.; Martínez-González, M.A.; López-Sabater, M.C.; Covas, M.I.; Corella, D.; Salas-Salvadó, J.; Gómez-Gracia, E.; Lapetra, J.; et al. Polyphenol intake and mortality risk: A re-analysis of the PREDIMED trial. BMC Med. 2014, 12, 77. [Google Scholar] [CrossRef]
- Vang, O.; Ahmad, N.; Baile, C.A.; Baur, J.A.; Brown, K.; Csiszar, A.; Das, D.K.; Delmas, D.; Gottfried, C.; Lin, H.Y.; et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 2011, 6, e19881. [Google Scholar] [CrossRef]
- Vang, O. What is new for resveratrol? Is a new set of recommendations necessary? Ann. N. Y. Acad. Sci. 2013, 1290, 1–11. [Google Scholar] [CrossRef]
- Cottart, C.H.; Nivet-Antoine, V.; Beaudeux, J.L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 2014, 58, 7–21. [Google Scholar] [CrossRef]
- Rauf, A.; Imran, M.; Butt, M.S.; Nadeem, M.; Peters, D.G.; Mubarak, M.S. Resveratrol as an anti-cancer agent: A review. Crit. Rev. Food Sci. Nutr. 2018, 58, 1428–1447. [Google Scholar] [CrossRef]
- Aluyen, J.K.; Ton, Q.N.; Tran, T.; Yang, A.E.; Gottlieb, H.B.; Bellanger, R.A. Resveratrol: Potential as anticancer agent. J. Diet. Suppl. 2012, 9, 45–56. [Google Scholar] [CrossRef]
- Varoni, E.M.; Lo Faro, A.F.; Sharifi-Rad, J.; Iriti, M. Anticancer Molecular Mechanisms of Resveratrol. Front. Nutr. 2016, 3, 8. [Google Scholar] [CrossRef]
- Suh, D.H.; Kim, M.K.; Kim, H.S.; Chung, H.H.; Song, Y.S. Cancer-specific Therapeutic Potential of Resveratrol: Metabolic Approach against Hallmarks of Cancer. Funct. Foods Health Dis. 2013, 3, 332–343. [Google Scholar] [CrossRef]
- Suh, D.H.; Kim, M.K.; Kim, H.S.; Chung, H.H.; Song, Y.S. Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front. Oncol. 2013, 3, 40670. [Google Scholar] [CrossRef]
- Jiang, H.; Shang, X.; Wu, H.; Gautam, S.C.; Al-Holou, S.; Li, C.; Kuo, J.; Zhang, L.; Chopp, M. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J. Exp. Ther. Oncol. 2009, 8, 25. [Google Scholar]
- Shulga, N.; Wilson-Smith, R.; Pastorino, J.G. Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 2009, 8, 3355–3364. [Google Scholar] [CrossRef]
- Furtado, C.M.; Marcondes, M.C.; Sola-Penna, M.; de Souza, M.L.S.; Zancan, P. Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLoS ONE 2012, 7, e30462. [Google Scholar] [CrossRef]
- Gomez, L.S.; Zancan, P.; Marcondes, M.C.; Ramos-Santos, L.; Meyer-Fernandes, J.R.; Sola-Penna, M.; Da Silva, D. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 2013, 95, 1336–1343. [Google Scholar] [CrossRef]
- Wolter, F.; Akoglu, B.; Clausnitzer, A.; Stein, J. Downregulation of the Cyclin D1/Cdk4 Complex Occurs during Resveratrol-Induced Cell Cycle Arrest in Colon Cancer Cell Lines. J. Nutr. 2001, 131, 2197–2203. [Google Scholar] [CrossRef]
- Kraft, T.E.; Parisotto, D.; Schempp, C.; Efferth, T. Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit. Rev. Food Sci. Nutr. 2009, 49, 782–799. [Google Scholar] [CrossRef]
- Liang, Y.C.; Tsai, S.H.; Chen, L.; Lin-Shiau, S.Y.; Lin, J.K. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem. Pharmacol. 2003, 65, 1053–1060. [Google Scholar] [CrossRef]
- Meghwal, M.; Goswami, T.K. Piper nigrum and piperine: An update. Phytother. Res. 2013, 27, 1121–1130. [Google Scholar] [CrossRef]
- Derosa, G.; Maffioli, P.; Sahebkar, A. Piperine and Its Role in Chronic Diseases. Adv. Exp. Med. Biol. 2016, 928, 173–184. [Google Scholar]
- Quijia, C.R.; Araujo, V.H.; Chorilli, M. Piperine: Chemical, biological and nanotechnological applications. Acta Pharm. 2021, 71, 185–213. [Google Scholar] [CrossRef]
- Ahmed, M.; Rahman, M.W.; Rahman, M.T.; Hossain, C. Analgesic principle from the bark of Careya arborea. Pharmazie 2002, 57, 698–701. [Google Scholar]
- Gorgani, L.; Mohammadi, M.; Najafpour, G.D.; Nikzad, M. Piperine-The Bioactive Compound of Black Pepper: From Isolation to Medicinal Formulations. Compr. Rev. Food Sci. Food Saf. 2017, 16, 124–140. [Google Scholar] [CrossRef]
- Chopra, B.; Dhingra, A.K.; Kapoor, R.P.; Prasad, D.N. Piperine and Its Various Physicochemical and Biological Aspects: A Review. Open Chem. J. 2017, 3, 75–96. [Google Scholar] [CrossRef]
- Haq, I.U.; Imran, M.; Nadeem, M.; Tufail, T.; Gondal, T.A.; Mubarak, M.S. Piperine: A review of its biological effects. Phytother. Res. 2021, 35, 680–700. [Google Scholar] [CrossRef]
- Greenshields, A.L.; Doucette, C.D.; Sutton, K.M.; Madera, L.; Annan, H.; Yaffe, P.B.; Knickle, A.F.; Dong, Z.; Hoskin, D.W. Piperine inhibits the growth and motility of triple-negative breast cancer cells. Cancer Lett. 2015, 357, 129–140. [Google Scholar] [CrossRef]
- Zhang, J.; Zhu, X.; Li, H.; Li, B.; Sun, L.; Xie, T.; Zhu, T.; Zhou, H.; Ye, Z. Piperine inhibits proliferation of human osteosarcoma cells via G2/M phase arrest and metastasis by suppressing MMP-2/-9 expression. Int. Immunopharmacol. 2015, 24, 50–58. [Google Scholar] [CrossRef]
- Jafri, A.; Siddiqui, S.; Rais, J.; Ahmad, M.S.; Kumar, S.; Jafar, T.; Afzal, M.; Arshad, M. Induction of apoptosis by piperine in human cervical adenocarcinoma via ROS mediated mitochondrial pathway and caspase-3 activation. EXCLI J. 2019, 18, 154–164. [Google Scholar]
- Si, L.; Yang, R.; Lin, R.; Yang, S. Piperine functions as a tumor suppressor for human ovarian tumor growth via activation of JNK/p38 MAPK-mediated intrinsic apoptotic pathway. Biosci. Rep. 2018, 38, BSR20180503. [Google Scholar] [CrossRef]
- Sriwiriyajan, S.; Tedasen, A.; Lailerd, N.; Boonyaphiphat, P.; Nitiruangjarat, A.; Deng, Y.; Graidist, P. Anticancer and Cancer Prevention Effects of Piperine-Free Piper nigrum Extract on N-nitrosomethylurea-Induced Mammary Tumorigenesis in Rats. Cancer Prev. Res. 2016, 9, 74–82. [Google Scholar] [CrossRef] [PubMed]
- Benayad, S.; Wahnou, H.; El Kebbaj, R.; Liagre, B.; Sol, V.; Oudghiri, M.; Saad, E.M.; Duval, R.E.; Limami, Y. The Promise of Piperine in Cancer Chemoprevention. Cancers 2023, 15, 5488. [Google Scholar] [CrossRef]
- Spagnuolo, C.; Russo, G.L.; Orhan, I.E.; Habtemariam, S.; Daglia, M.; Sureda, A.; Nabavi, S.F.; Devi, K.P.; Loizzo, M.R.; Tundis, R.; et al. Genistein and cancer: Current status, challenges, and future directions. Adv. Nutr. 2015, 6, 408–419. [Google Scholar] [CrossRef] [PubMed]
- Ganai, A.A.; Farooqi, H. Bioactivity of genistein: A review of in vitro and in vivo studies. Biomed. Pharmacother. 2015, 76, 30–38. [Google Scholar] [CrossRef]
- Banerjee, S.; Li, Y.; Wang, Z.; Sarkar, F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008, 269, 226–242. [Google Scholar] [CrossRef] [PubMed]
- Mukund, V.; Mukund, D.; Sharma, V.; Mannarapu, M.; Alam, A. Genistein: Its role in metabolic diseases and cancer. Crit. Rev. Oncol. Hematol. 2017, 119, 13–22. [Google Scholar] [CrossRef] [PubMed]
- Pan, H.; Zhou, W.; He, W.; Liu, X.; Ding, Q.; Ling, L.; Zha, X.; Wang, S. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway. Int. J. Mol. Med. 2012, 30, 337–343. [Google Scholar] [CrossRef]
- da Silva, H.B.; Amaral, E.P.; Nolasco, E.L.; de Victo, N.C.; Atique, R.; Jank, C.C.; Anschau, V.; Zerbini, L.F.; Correa, R.G. Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer 2013, 2013, 920612. [Google Scholar] [CrossRef]
- Zhang, Z.; Wang, C.Z.; Du, G.J.; Qi, L.W.; Calway, T.; He, T.C.; Du, W.; Yuan, C.S. Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells. Int. J. Oncol. 2013, 43, 289–296. [Google Scholar] [CrossRef]
- Gu, Y.; Zhu, C.F.; Dai, Y.L.; Zhong, Q.; Sun, B. Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma. World J. Gastroenterol. WJG 2009, 15, 4952. [Google Scholar] [CrossRef]
- Borlinghaus, J.; Albrecht, F.; Gruhlke, M.C.H.; Nwachukwu, I.D.; Slusarenko, A.J. Allicin: Chemistry and Biological Properties. Molecules 2014, 19, 12591. [Google Scholar] [CrossRef] [PubMed]
- Salehi, B.; Zucca, P.; Orhan, I.E.; Azzini, E.; Adetunji, C.; Mohammed, S.; Banerjee, S.; Sharopov, F.; Rigano, D.; Sharifi-Rad, J.; et al. Allicin and health: A comprehensive review. Trends Food Sci. Technol. 2019, 86, 502–516. [Google Scholar] [CrossRef]
- Marchese, A.; Barbieri, R.; Sanches-Silva, A.; Daglia, M.; Nabavi, S.; Jafari, N.; Izadi, M.; Ajami, M.; Nabavi, S. Antifungal and antibacterial activities of allicin: A review. Trends Food Sci. Technol. 2016, 52, 49–56. [Google Scholar] [CrossRef]
- Fujisawa, H.; Suma, K.; Origuchi, K.; Seki, T.; Ariga, T. Thermostability of allicin determined by chemical and biological assays. Biosci. Biotechnol. Biochem. 2008, 72, 2877–2883. [Google Scholar] [CrossRef] [PubMed]
- Miron, T.; Wilchek, M.; Sharp, A.; Nakagawa, Y.; Naoi, M.; Nozawa, Y.; Akao, Y. Allicin inhibits cell growth and induces apoptosis through the mitochondrial pathway in HL60 and U937 cells. J. Nutr. Biochem. 2008, 19, 524–535. [Google Scholar] [CrossRef] [PubMed]
- Bat-Chen, W.; Golan, T.; Peri, I.; Ludmer, Z.; Schwartz, B. Allicin purified from fresh garlic cloves induces apoptosis in colon cancer cells via Nrf2. Nutr. Cancer 2010, 62, 947–957. [Google Scholar] [CrossRef]
- Xiang, Y.; Zhao, J.; Zhao, M.; Wang, K. Allicin activates autophagic cell death to alleviate the malignant development of thyroid cancer. Exp. Ther. Med. 2018, 15, 3537–3543. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.; Zhu, B.; Zhao, L.; Liu, Y.; Zhao, F.; Feng, J.; Jin, Y.; Sun, J.; Geng, R.; Wei, Y. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma. Cell. Physiol. Biochem. 2018, 47, 641–653. [Google Scholar] [CrossRef] [PubMed]
- Huang, L.; Song, Y.; Lian, J.; Wang, Z. Allicin inhibits the invasion of lung adenocarcinoma cells by altering tissue inhibitor of metalloproteinase/matrix metalloproteinase balance via reducing the activity of phosphoinositide 3-Kinase/AKT Signaling. Oncol. Lett. 2017, 14, 468–474. [Google Scholar] [CrossRef]
- Alhasan, L.; Addai, Z.R. Allicin-induced modulation of angiogenesis in lung cancer cells (A549). Trop. J. Pharm. Res. 2019, 17, 2129–2134. [Google Scholar] [CrossRef]
- Tauber, A.L.; Schweiker, S.S.; Levonis, S.M. From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer. Nutr. Res. 2020, 74, 23–36. [Google Scholar] [CrossRef] [PubMed]
- Ni, J.; Guo, X.; Wang, H.; Zhou, T.; Wang, X. Differences in the Effects of EGCG on Chromosomal Stability and Cell Growth between Normal and Colon Cancer Cells. Molecules 2018, 23, 788. [Google Scholar] [CrossRef] [PubMed]
- Jiang, S.; Huang, C.; Zheng, G.; Yi, W.; Wu, B.; Tang, J.; Liu, X.; Huang, B.; Wu, D.; Yan, T.; et al. EGCG Inhibits Proliferation and Induces Apoptosis Through Downregulation of SIRT1 in Nasopharyngeal Carcinoma Cells. Front. Nutr. 2022, 9, 851972. [Google Scholar] [CrossRef] [PubMed]
- Huang, C.Y.; Han, Z.; Li, X.; Xie, H.H.; Zhu, S.S. Mechanism of egcg promoting apoptosis of MCF–7 cell line in human breast cancer. Oncol. Lett. 2017, 14, 3623–3627. [Google Scholar] [CrossRef]
- Datta, S.; Sinha, D. Low dose epigallocatechin-3-gallate revives doxorubicin responsiveness by a redox-sensitive pathway in A549 lung adenocarcinoma cells. J. Biochem. Mol. Toxicol. 2022, 36, e22999. [Google Scholar] [CrossRef] [PubMed]
- Masuda, M.; Suzui, M.; Lim, J.T.E.; Deguchi, A.; Soh, J.W.; Weinstein, I.B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J. Exp. Ther. Oncol. 2002, 2, 350–359. [Google Scholar] [CrossRef]
- Giordano, A.; Tommonaro, G. Curcumin and Cancer. Nutrients 2019, 11, 2376. [Google Scholar] [CrossRef]
- Bose, S.; Panda, A.K.; Mukherjee, S.; Sa, G. Curcumin and tumor immune-editing: Resurrecting the immune system. Cell Div. 2015, 10, 6. [Google Scholar] [CrossRef]
- Wang, C.; Song, X.; Shang, M.; Zou, W.; Zhang, M.; Wei, H.; Shao, H. Curcumin exerts cytotoxicity dependent on reactive oxygen species accumulation in non-small-cell lung cancer cells. Future Oncol. 2019, 15, 1243–1253. [Google Scholar] [CrossRef]
- Smagurauskaite, G.; Mahale, J.; Brown, K.; Thomas, A.L.; Howells, L.M. New Paradigms to Assess Consequences of Long-Term, Low-Dose Curcumin Exposure in Lung Cancer Cells. Molecules 2020, 25, 366. [Google Scholar] [CrossRef]
- Hu, S.; Xu, Y.; Meng, L.; Huang, L.; Sun, H. Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp. Ther. Med. 2018, 16, 1266–1272. [Google Scholar] [CrossRef] [PubMed]
- Anuchapreeda, S.; Thanarattanakorn, P.; Sittipreechacharn, S.; Chanarat, P.; Limtrakul, P. Curcumin inhibits WT1 gene expression in human leukemic K562 cells. Acta Pharmacol. Sin. 2006, 27, 360–366. [Google Scholar] [CrossRef]
- Xue, X.; Yu, J.L.; Sun, D.Q.; Kong, F.; Qu, X.J.; Zou, W.; Wu, J.; Wang, R.M. Curcumin induces apoptosis in SGC-7901 gastric adenocarcinoma cells via regulation of mitochondrial signaling pathways. Asian Pac. J. Cancer Prev. 2014, 15, 3987–3992. [Google Scholar] [CrossRef] [PubMed]
- Hsu, S.C.; Chung, J.G. Anticancer potential of emodin. Biomedicine 2012, 2, 108–116. [Google Scholar] [CrossRef] [PubMed]
- Wei, W.T.; Lin, S.Z.; Liu, D.L.; Wang, Z.H. The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). Oncol. Rep. 2013, 30, 2555–2562. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Jin, S.; Cao, Y.; Xu, J.; Zhu, S.; Li, Z. Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway. Cancer Cell Int. 2021, 21, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Peng, S.; Wang, J.; Lu, C.; Xu, Z.; Chai, J.J.; Ke, Q.; Deng, X.Z. Emodin enhances cisplatin sensitivity in non-small cell lung cancer through Pgp downregulation. Oncol. Lett. 2021, 21, 230. [Google Scholar] [CrossRef]
- Han, Y.M.; Lee, S.K.; Jeong, D.G.; Ryu, S.; Han, D.; Kim, D.; Kwon, B. Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity. Bioorg. Med. Chem. Lett. 2012, 22, 323–326. [Google Scholar] [CrossRef]
- Huang, Z.; Chen, G.; Shi, P. Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway. Arch. Pharm. Res. 2008, 31, 742–748. [Google Scholar] [CrossRef]
- Yu, C.X.; Zhang, X.Q.; Kang, L.D.; Zhang, P.J.; Chen, W.W.; Liu, W.W.; Liu, Q.W.; Zhang, J.Y. Emodin induces apoptosis in human prostate cancer cell LNCaP. Asian J. Androl. 2008, 10, 625–634. [Google Scholar] [CrossRef]
- Wang, Z.H.; Chen, H.; Guo, H.C.; Tong, H.F.; Liu, J.X.; Wei, W.T.; Tan, W.; Ni, Z.L.; Liu, H.B.; Lin, S.Z. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int. J. Oncol. 2011, 39, 1123–1131. [Google Scholar] [PubMed]
- Mathema, V.B.; Koh, Y.S.; Thakuri, B.C.; Sillanpää, M. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation 2012, 35, 560–565. [Google Scholar] [CrossRef] [PubMed]
- Jafari, N.; Nazeri, S.; Enferadi, S.T. Parthenolide reduces metastasis by inhibition of vimentin expression and induces apoptosis by suppression elongation factor α—1 expression. Phytomedicine 2018, 41, 67–73. [Google Scholar] [CrossRef]
- Karam, L.; Abou Staiteieh, S.; Chaaban, R.; Hayar, B.; Ismail, B.; Neipel, F.; Darwiche, N.; Abou Merhi, R. Anticancer activities of parthenolide in primary effusion lymphoma preclinical models. Mol. Carcinog. 2021, 60, 567–581. [Google Scholar] [CrossRef]
- Carlisi, D.; Lauricella, M.; D’anneo, A.; De Blasio, A.; Celesia, A.; Pratelli, G.; Notaro, A.; Calvaruso, G.; Giuliano, M.; Emanuele, S. Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties. Biomedicines 2022, 10, 514. [Google Scholar] [CrossRef]
- Liu, D.; Han, Y.; Liu, L.; Ren, X.; Zhang, H.; Fan, S.; Qin, T.; Li, L. Parthenolide inhibits the tumor characteristics of renal cell carcinoma. Int. J. Oncol. 2021, 58, 100–110. [Google Scholar] [CrossRef]
- Sun, L.; Yuan, W.; Wen, G.; Yu, B.; Xu, F.; Gan, X.; Tang, J.; Zeng, Q.; Zhu, L.; Chen, C.; et al. Parthenolide inhibits human lung cancer cell growth by modulating the IGF-1R/PI3K/Akt signaling pathway. Oncol. Rep. 2020, 44, 1184–1193. [Google Scholar] [CrossRef] [PubMed]
- Jeyamohan, S.; Moorthy, R.K.; Kannan, M.K.; Arockiam, A.J.V. Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer. Biotechnol. Lett. 2016, 38, 1251–1260. [Google Scholar] [CrossRef]
- Lin, Y.; Shi, R.; Wang, X.; Shen, H.-M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Targets 2008, 8, 634–646. [Google Scholar] [CrossRef]
- Lim, D.Y.; Jeong, Y.; Tyner, A.L.; Park, J.H.Y. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G66–G75. [Google Scholar] [CrossRef]
- Wu, H.T.; Liu, Y.E.; Hsu, K.W.; Wang, Y.F.; Chan, Y.C.; Chen, Y.; Chen, D.R. MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway. Am. J. Chin. Med. 2020, 48, 1221–1241. [Google Scholar] [CrossRef] [PubMed]
- You, Y.; Wang, R.; Shao, N.; Zhi, F.; Yang, Y. Luteolin suppresses tumor proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. Onco Targets Ther. 2019, 12, 2383. [Google Scholar] [CrossRef] [PubMed]
- Potočnjak, I.; Šimić, L.; Gobin, I.; Vukelić, I.; Domitrović, R. Antitumor activity of luteolin in human colon cancer SW620 cells is mediated by the ERK/FOXO3a signaling pathway. Toxicol. In Vitro 2020, 66, 104852. [Google Scholar] [CrossRef]
- Kashyap, D.; Mittal, S.; Sak, K.; Singhal, P.; Tuli, H.S. Molecular mechanisms of action of quercetin in cancer: Recent advances. Tumour Biol. 2016, 37, 12927–12939. [Google Scholar] [CrossRef]
- Chou, C.C.; Yang, J.S.; Lu, H.F.; Ip, S.W.; Lo, C.; Wu, C.C.; Lin, J.P.; Tang, N.Y.; Chung, J.G.; Chou, M.J.; et al. Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. Arch. Pharm. Res. 2010, 33, 1181–1191. [Google Scholar] [CrossRef] [PubMed]
- Niu, G.; Yin, S.; Xie, S.; Li, Y.; Nie, D.; Ma, L.; Wang, X.; Wu, Y. Quercetin induces apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in human HL-60 cells. Acta Biochim. Biophys. Sin. 2011, 43, 30–37. [Google Scholar] [CrossRef]
- Russo, M.; Spagnuolo, C.; Bilotto, S.; Tedesco, I.; Maiani, G.; Russo, G.L. Inhibition of protein kinase CK2 by quercetin enhances CD95-mediated apoptosis in a human thymus-derived T cell line. Food Res. Int. 2014, 63, 244–251. [Google Scholar] [CrossRef]
- Haghiac, M.; Walle, T. Quercetin induces necrosis and apoptosis in SCC-9 oral cancer cells. Nutr. Cancer 2005, 53, 220–231. [Google Scholar] [CrossRef]
- Ong, C.S.; Tran, E.; Nguyen, T.T.T.; Ong, C.K.; Lee, S.K.; Lee, J.J.; Ng, C.P.; Leong, C.; Huynh, H. Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol. Rep. 2004, 11, 727–733. [Google Scholar] [CrossRef]
- Cao, H.H.; Tse, A.K.W.; Kwan, H.Y.; Yu, H.; Cheng, C.Y.; Su, T.; Fong, W.F.; Yu, Z.L. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem. Pharmacol. 2014, 87, 424–434. [Google Scholar] [CrossRef]
- Mottaghipisheh, J.; Doustimotlagh, A.H.; Irajie, C.; Tanideh, N.; Barzegar, A.; Iraji, A. The Promising Therapeutic and Preventive Properties of Anthocyanidins/Anthocyanins on Prostate Cancer. Cells 2022, 11, 1070. [Google Scholar] [CrossRef]
- Khoo, H.E.; Azlan, A.; Tang, S.T.; Lim, S.M. Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr. Res. 2017, 61, 1361779. [Google Scholar] [CrossRef] [PubMed]
- Talib, W.H.; Awajan, D.; Hamed, R.A.; Azzam, A.O.; Mahmod, A.I.; AL-Yasari, I.H. Combination Anticancer Therapies Using Selected Phytochemicals. Molecules 2022, 27, 5452. [Google Scholar] [CrossRef] [PubMed]
- Lu, J.N.; Panchanathan, R.; Lee, W.S.; Kim, H.J.; Kim, D.H.; Choi, Y.H.; Kim, G.S.; Shin, S.C.; Hong, S.C. Anthocyanins from the Fruit of Vitis Coignetiae Pulliat Inhibit TNF-Augmented Cancer Proliferation, Migration, and Invasion in A549 Cells. Asian Pac. J. Cancer Prev. 2017, 18, 2919–2923. [Google Scholar]
- Lage, N.N.; Layosa, M.A.A.; Arbizu, S.; Chew, B.; Pedrosa, M.; Mertens-Talcott, S.; Talcott, S.; Noratto, G. Dark sweet cherry (Prunus avium) phenolics enriched in anthocyanins exhibit enhanced activity against the most aggressive breast cancer subtypes without toxicity to normal breast cells. J. Funct. Foods 2020, 64, 103710. [Google Scholar] [CrossRef]
- López De Las Hazas, M.C.; Mosele, J.I.; Macià, A.; Ludwig, I.A.; Motilva, M.J. Exploring the Colonic Metabolism of Grape and Strawberry Anthocyanins and Their in Vitro Apoptotic Effects in HT-29 Colon Cancer Cells. J. Agric. Food Chem. 2017, 65, 6477–6487. [Google Scholar] [CrossRef]
- Mazewski, C.; Kim, M.S.; Gonzalez de Mejia, E. Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico. Sci. Rep. 2019, 9, 11560. [Google Scholar] [CrossRef] [PubMed]
- Bishayee, A.; Mbimba, T.; Thoppil, R.J.; Háznagy-Radnai, E.; Sipos, P.; Darvesh, A.S.; Folkesson, H.G.; Hohmann, J. Anthocyanin-rich black currant (Ribes nigrum L.) extract affords chemoprevention against diethylnitrosamine-induced hepatocellular carcinogenesis in rats. J. Nutr. Biochem. 2011, 22, 1035–1046. [Google Scholar] [CrossRef]
- Thi, N.; Do Hwang, E.S. Effects of black chokeberry extracts on metastasis and cell-cycle arrest in SK-Hep1 human liver cancer cell line. Asian Pac. J. Trop. Biomed. 2018, 8, 285–291. [Google Scholar]
- Anand, P.; Kunnumakara, A.B.; Sundaram, C.; Harikumar, K.B.; Tharakan, S.T.; Lai, O.S.; Sung, B.; Aggarwal, B.B. Cancer is a Preventable Disease that Requires Major Lifestyle Changes. Pharm. Res. 2008, 25, 2097. [Google Scholar] [CrossRef]
- Bahrami, H.; Tafrihi, M.; Mohamadzadeh, S.; Bahrami, H. Reversing the Warburg effect to control cancer: A review of diet-based solutions. J. Curr. Oncol. Med. Sci. 2022, 2, 234–248. [Google Scholar]
- Bahrami, H.; Greiner, T. The Alkaline Diet and the Warburg Effect. World Nutr. 2021, 12, 20–39. [Google Scholar] [CrossRef]
- Mittelman, S.D. The Role of Diet in Cancer Prevention and Chemotherapy Efficacy. Annu. Rev. Nutr. 2020, 40, 273–297. [Google Scholar] [CrossRef] [PubMed]
- Jo, J.Y.; de Mejia, E.G.; Lila, M.A. Cytotoxicity of bioactive polymeric fractions from grape cell culture on human hepatocellular carcinoma, murine leukemia and non-cancerous PK15 kidney cells. Food Chem. Toxicol. 2006, 44, 1758–1767. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.-Z.; Ma, Q.; Kim, S.; Wang, D.H.; Shoyama, Y.; Yuan, C.-S. Effects of saffron and its active constituent crocin on cancer management: A narrative review. Longhua Chin. Med. 2022, 5, 35. [Google Scholar] [CrossRef] [PubMed]
- Phillips, C.M.; Chen, L.W.; Heude, B.; Bernard, J.Y.; Harvey, N.C.; Duijts, L.; Mensink-Bout, S.M.; Polanska, K.; Mancano, G.; Suderman, M.; et al. Dietary Inflammatory Index and Non-Communicable Disease Risk: A Narrative Review. Nutrients 2019, 11, 1873. [Google Scholar] [CrossRef]
- West, L.; Yin, Y.; Pierce, S.R.; Fang, Z.; Fan, Y.; Sun, W.; Tucker, K.; Staley, A.; Zhou, C.; Bae-Jump, V. Docosahexaenoic acid (DHA), an omega-3 fatty acid, inhibits tumor growth and metastatic potential of ovarian cancer. Am. J. Cancer Res. 2020, 10, 4450–4463. [Google Scholar] [PubMed]
- Namazi, N.; Larijani, B.; Azadbakht, L. Association between the dietary inflammatory index and the incidence of cancer: A systematic review and meta-analysis of prospective studies. Public Health 2018, 164, 148–156. [Google Scholar] [CrossRef]
- De Silva, S.F.; Alcorn, J. Flaxseed Lignans as Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets. Pharmaceuticals 2019, 12, 68. [Google Scholar] [CrossRef]
- Kajla, P.; Sharma, A.; Sood, D.R. Flaxseed—A potential functional food source. J. Food Sci. Technol. 2015, 52, 1857. [Google Scholar] [CrossRef]
- Bahrami, H.; Tafrihi, M. Global trends of cancer: The role of diet, lifestyle, and environmental factors. Cancer Innov. 2023, 2, 290–301. [Google Scholar] [CrossRef] [PubMed]
- Hardt, L.; Mahamat-Saleh, Y.; Aune, D.; Schlesinger, S. Plant-Based Diets and Cancer Prognosis: A Review of Recent Research. Curr. Nutr. Rep. 2022, 11, 695–716. [Google Scholar] [CrossRef] [PubMed]
- Crosby, L.; Davis, B.; Joshi, S.; Jardine, M.; Paul, J.; Neola, M.; Barnard, N.D. Ketogenic Diets and Chronic Disease: Weighing the Benefits Against the Risks. Front. Nutr. 2021, 8, 702802. [Google Scholar] [CrossRef] [PubMed]
Bioactive Compound | Food Source | Targeted Hallmarks | Type of Cancer | Concentration/ Dose Used | Experimental Model | References |
---|---|---|---|---|---|---|
Thymoquinone (TQ) | Nigella sativa (Black seed) | Resisting cell death, enabling replicative immortality, and sustaining proliferative signaling | Hepatocellular carcinoma | 20 mg/kg | In vivo | [76] |
Esophageal cancer | 5–10 mg/kg | In vivo | [80] | |||
Resveratrol | Grape skin and seeds, peanuts, berries, and tea | Reprogramming cellular metabolism, resisting cell death, sustaining proliferative signaling, and enabling replicative immortality | Human breast cancer | 2.5–10 μM | In vitro | [101] |
Colon cancer | 12.5–200 μmol/L | In vitro | [102] | |||
Piperine | Piper nigrum, Piper longum, Rhododendron faurie, Vicoa indica, Anethum sowa, Fructus piperis longi, and Careya arborea | Enabling replicative immortality, resisting cell death, activating invasion and metastasis, and sustaining proliferative signaling | Colon cancer | 75–150 μM | In vitro | [112] |
Ovarian cancer | 8 µM | In vitro | [115] | |||
Genistein | Soy products and plants, including alfalfa, barley meal, broccoli, cauliflower, sunflower seeds, caraway, and clover seeds | Enabling replicative immortality, resisting cell death, and activating invasion and metastasis | Triple-negative breast cancer | 5–20 µM | In vitro | [122] |
Human colon cancer | 25–100 µM | In vitro | [124] | |||
Hepatocellular carcinoma | 10 and 20 µM | In vitro | [125] | |||
Allicin | White garlic (A. sativum L.), elephant garlic (A. ampeloprasum L.), wild garlic (A. ursinum L.), field garlic (A. vineale L.), and alpine leek (A. victorialis L.) | Sustaining proliferative signaling, resisting cell death, inducing or accessing vasculature, avoiding immune destruction, and activating invasion and metastasis | Human promyelocytic leukemia, and human myelomonocytic leukemia | 5 μM | In vitro | [130] |
Thyroid cancer | 10 μM | In vitro | [132] | |||
Cholangiocarcinoma | 40 µM | In vitro | [133] | |||
Lung adenocarcinoma | 15 and 20 µM | In vitro | [134] | |||
Epigallocatechin gallate (EGCG) | Green tea, black tea, oolong tea, and in small amounts in various fruits and vegetables | Sustaining proliferative signaling, resisting cell death, and inducing or accessing vasculature | Colon adenocarcinoma | 5–40 µg/mL | In vitro | [137] |
Nasopharyngeal carcinoma | 40 µM | In vitro | [138] | |||
Breast cancer | 30 µmol/L | In vitro | [139] | |||
Lung adenocarcinoma | 0.5 µM | In vitro | [140] | |||
Head, neck, and breast carcinomas | 30 µg/mL | In vitro | [141] | |||
Curcumin | Rhizome of Curcuma longa (turmeric) and other Curcuma species | Enabling replicative immortality, resisting cell death, activating invasion and metastasis, and sustaining proliferative signaling | Non-small-cell lung cancer | 0.25 and 0.5 µM | In vitro | [145] |
Emodin | Root and rhizome of Rheum palmatum | Resisting cell death, enabling replicative immortality, sustaining proliferative signaling, and activating invasion and metastasis | Non-small-cell lung cancer | 5 µM | In vitro | [152] |
Parthenolide (PTL) | Feverfew plant (Tanacetum parthenium) | Resisting cell death, sustaining proliferative signaling, and enabling replicative immortality | Renal cell carcinoma | 4 and 8 µM | In vitro | [161] |
Lung cancer | 1–50 µM | In vitro | [162] | |||
Cervical cancer | 6 µM | In vitro | [163] | |||
Luteolin | Vegetables and fruits such as celery, parsley, broccoli, onion leaves, carrots, peppers, cabbages, and apple skins | Resisting cell death and sustaining proliferative signaling | Human colon cancer | 40 µmol/L | In vitro | [165] |
Tamoxifen- resistant breast cancer | 10, 20, and 30 μM | In vitro | [166] | |||
Glioma | 30 µM | In vitro | [167] | |||
Quercetin | Fruits, and vegetables, including onions, buckwheat, and broccoli | Resisting cell death, sustaining proliferative signaling, enabling replicative immortality and inducing or accessing vasculature | Breast cancer | 10–175 µM | In vitro | [170] |
Leukemia | 25, 50 and 100 µM | In vitro | [171] | |||
Oral squamous carcinoma | 50–200 µM | In vitro | [173] | |||
Nasopharyngeal carcinoma | 14.8 and 52.1 µM | In vitro | [174] | |||
Anthocyanins | Fruits and vegetables, including berries, pomegranates, and rice | Resisting cell death, sustaining proliferative signaling, inducing or accessing vasculature, and activating invasion and metastasis | Lung cancer | 6.25 and 100 µg/mL | In vitro | [179] |
Colon cancer | 100 µmol/L | In vitro | [181] | |||
Liver cancer | 100–200 µg/mL | In vitro | [184] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Talib, W.H.; Abed, I.; Raad, D.; Alomari, R.K.; Jamal, A.; Jabbar, R.; Alhasan, E.O.A.; Alshaeri, H.K.; Alasmari, M.M.; Law, D. Targeting Cancer Hallmarks Using Selected Food Bioactive Compounds: Potentials for Preventive and Therapeutic Strategies. Foods 2024, 13, 2687. https://doi.org/10.3390/foods13172687
Talib WH, Abed I, Raad D, Alomari RK, Jamal A, Jabbar R, Alhasan EOA, Alshaeri HK, Alasmari MM, Law D. Targeting Cancer Hallmarks Using Selected Food Bioactive Compounds: Potentials for Preventive and Therapeutic Strategies. Foods. 2024; 13(17):2687. https://doi.org/10.3390/foods13172687
Chicago/Turabian StyleTalib, Wamidh H., Ilia Abed, Daniah Raad, Raghad K. Alomari, Ayah Jamal, Rand Jabbar, Eman Omar Amin Alhasan, Heba K. Alshaeri, Moudi M. Alasmari, and Douglas Law. 2024. "Targeting Cancer Hallmarks Using Selected Food Bioactive Compounds: Potentials for Preventive and Therapeutic Strategies" Foods 13, no. 17: 2687. https://doi.org/10.3390/foods13172687